COMPANY

NeuroGT

HQ: Chapel Hill, NC source · neurogt.com ↗ · Southeast

Clinical Phase 2

Keywords: neurology gene therapy mRNA Sanfilippo Syndrome (MPS III) rAAV9-CMV-hNAGLUop

Location: Chapel Hill, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)7NIH grants

Funding and NIH signals

NIH award NIH awarded $1.48M (SBIR Phase II 5R44NS143501-02, continuation, notice Sep 14, 2026); 3 NIH awards totaling $3.17M in the last 12 months. NIH RePORTER 5R44NS143501-02 (Sep 14, 2026)
Evidence (3 events)
- Sep 14, 2026 · NIH RePORTER 5R44NS143501-02
  Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R44NS143501-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1484525; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I; Organization type: Domestic For-Profits
- Sep 14, 2026 · NIH RePORTER 5R44NS135667-03
  Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R44NS135667-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1341983; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of gene therapy product for treating MPS IIIB; Organization type: Domestic For-Profits
- May 12, 2026 · NIH RePORTER 5R41NS143578-02
  Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R41NS143578-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 342740; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jan 18, 2027 Trial start Phase 1/Phase 2: Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB source ↗
Sep 14, 2026 Grant Government grant — SBIR: $1.48M (annual award, as published), announced Sep 14, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 14, 2026 Grant Government grant — SBIR: $1.34M (annual award, as published), announced Sep 14, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
May 12, 2026 Grant Government grant — STTR: $342,740 (annual award, as published), announced May 12, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 16, 2025 Grant Government grant — SBIR: $1.5M (annual award, as published), announced Sep 16, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 3, 2025 Grant Government grant — SBIR: $1.31M (annual award, as published), announced Sep 3, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Jul 25, 2025 Grant Government grant — SBIR: $969,817 (annual award, as published), announced Jul 25, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 8, 2025 Grant Government grant — STTR: $349,909 (annual award, as published), announced Jul 8, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Upcoming milestones

Dec 31, 2028 (ESTIMATED) · Phase 1/Phase 2 · Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB · NCT07818759

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Sep 14, 2026 Government grant — SBIR: $1.48M (annual award, as published), announced Sep 14, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 14, 2026 Government grant — SBIR: $1.34M (annual award, as published), announced Sep 14, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
May 12, 2026 Government grant — STTR: $342,740 (annual award, as published), announced May 12, 2026. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 16, 2025 Government grant — SBIR: $1.5M (annual award, as published), announced Sep 16, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Sep 3, 2025 Government grant — SBIR: $1.31M (annual award, as published), announced Sep 3, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Jul 25, 2025 Government grant — SBIR: $969,817 (annual award, as published), announced Jul 25, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 8, 2025 Government grant — STTR: $349,909 (annual award, as published), announced Jul 8, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07818759	Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB	Phase 1/Phase 2	Not yet recruiting	Jan 18, 2027	Dec 31, 2028 (estimated)

NIH awards 7

Annual award amounts. Total $3.1M.

Aug 30, 2024 NIH award 1R44NS135667-01A1 FY2024: $456,414 awarded for that fiscal year; activity R44 (SBIR); PI MCCARTY, DOUGLAS M; recipient as written: NEUROGT, INC., Chapel Hill, NC. Development of gene therapy product for tre source ↗
Aug 8, 2024 NIH award 4R44AI172670-02 FY2024: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI MCCARTY, DOUGLAS M; recipient as written: NEUROGT, INC., Chapel Hill, NC. Protein depleting pre-existing antibodies f source ↗
Aug 16, 2023 NIH award 5R41NS127726-02 FY2023: $323,802 awarded for that fiscal year; activity R41 (STTR); PI FU, HAIYAN; recipient as written: NEUROGT, INC., Chapel Hill, NC. Develop AAV9 gene replacement therapy for treating MP source ↗
Jul 27, 2023 NIH award 1R44AI172670-01A1 FY2023: $306,500 awarded for that fiscal year; activity R44 (SBIR); PI MCCARTY, DOUGLAS M; recipient as written: NEUROGT, INC., Chapel Hill, NC. Protein depleting pre-existing antibodies f source ↗
Jul 29, 2022 NIH award 1R41NS127726-01A1 FY2022: $378,882 awarded for that fiscal year; activity R41 (STTR); PI FU, HAIYAN; recipient as written: NEUROGT, INC., Chapel Hill, NC. Develop AAV9 gene replacement therapy for treating source ↗
Mar 30, 2021 NIH award 5R41NS115232-02 FY2021: $284,425 awarded for that fiscal year; activity R41 (STTR); PI FU, HAIYAN; recipient as written: NEUROGT, INC., Chapel Hill, NC. Development of gene therapy product for treating MPS source ↗
Apr 7, 2020 NIH award 1R41NS115232-01A1 FY2020: $397,823 awarded for that fiscal year; activity R41 (STTR); PI FU, HAIYAN; recipient as written: NEUROGT, INC., Chapel Hill, NC. Development of gene therapy product for treating MP source ↗